Eli Lilly’s MDR-TB Partnership makes the case for IP’s role in accessible, sustainable healthcare
Eli Lilly has released details of its MDR-TB [multi-drug resistant tuberculosis] Partnership programme, under which it has transferred technology and knowhow relevant to its Cycloserine and Capreomycin treatments to pharmaceutical manufacturers in…
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.